| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.
|
Int J Cancer
|
2011
|
2.42
|
|
2
|
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
|
Nat Genet
|
2005
|
2.08
|
|
3
|
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.
|
Int J Cancer
|
2011
|
1.81
|
|
4
|
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
|
Mol Cancer
|
2010
|
1.64
|
|
5
|
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
|
Cancer Sci
|
2011
|
1.57
|
|
6
|
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
|
Cancer Res
|
2012
|
1.37
|
|
7
|
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
|
Neoplasia
|
2012
|
1.36
|
|
8
|
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
|
Cancer Res
|
2007
|
1.32
|
|
9
|
Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B.
|
Nat Commun
|
2012
|
1.27
|
|
10
|
Recognition of modification status on a histone H3 tail by linked histone reader modules of the epigenetic regulator UHRF1.
|
Proc Natl Acad Sci U S A
|
2012
|
1.22
|
|
11
|
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.
|
Cancer Res
|
2010
|
1.22
|
|
12
|
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
|
Neoplasia
|
2011
|
1.15
|
|
13
|
Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6).
|
J Biol Chem
|
2013
|
1.12
|
|
14
|
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
|
Int J Cancer
|
2011
|
1.09
|
|
15
|
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
|
Neoplasia
|
2011
|
1.08
|
|
16
|
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer.
|
Mol Cancer
|
2011
|
1.05
|
|
17
|
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
|
Cancer Prev Res (Phila)
|
2011
|
1.02
|
|
18
|
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
|
Genes Chromosomes Cancer
|
2012
|
1.00
|
|
19
|
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
|
Cancer Lett
|
2013
|
1.00
|
|
20
|
Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.
|
Cancer Res
|
2002
|
0.97
|
|
21
|
The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.
|
Neoplasia
|
2013
|
0.93
|
|
22
|
Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma.
|
Int J Oncol
|
2002
|
0.91
|
|
23
|
Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.
|
Cancer Res
|
2010
|
0.88
|
|
24
|
WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.
|
Neoplasia
|
2005
|
0.86
|
|
25
|
Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells.
|
Clin Cancer Res
|
2008
|
0.84
|